KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Shares Issued (2016 - 2025)

Sarepta Therapeutics has reported Shares Issued over the past 15 years, most recently at $2.8 million for Q3 2025.

  • For Q3 2025, Shares Issued rose 104.54% year-over-year to $2.8 million; the TTM value through Dec 2025 reached -$59.2 million, changed N/A, while the annual FY2025 figure was $20.0 million, N/A changed from the prior year.
  • Shares Issued for Q3 2025 was $2.8 million at Sarepta Therapeutics, up from -$62.1 million in the prior quarter.
  • Over five years, Shares Issued peaked at $39.9 million in Q2 2024 and troughed at -$62.1 million in Q3 2024.
  • A 5-year average of $3.4 million and a median of $5.9 million in 2021 define the central range for Shares Issued.
  • On a YoY basis, Shares Issued climbed as much as 1628.91% in 2023 and fell as far as 536.19% in 2023.
  • Year by year, Shares Issued stood at $2.1 million in 2021, then soared by 426.21% to $11.3 million in 2022, then tumbled by 536.19% to -$49.3 million in 2023, then decreased by 25.87% to -$62.1 million in 2024, then skyrocketed by 104.54% to $2.8 million in 2025.
  • Business Quant data shows Shares Issued for SRPT at $2.8 million in Q3 2025, -$62.1 million in Q3 2024, and $39.9 million in Q2 2024.